This open-label clinical trial examined the
efficacy and safety of a d-amino oxidase inhibitor, sodium benzoate, in the
treatment of non-communicative children with autism spectrum disorder.
We hypothesized that benzoate, through
indirect glutamate stimulation, may enhance learning in communication. Method:
Six children (five boys, one girl, 3-year-7-month to 9-year-6-month of age)
completed the 12 weeks of study
of receiving sodium benzoate in conjunction with communication training
program.
The outcome measures were Receptive and
Expressive Vocabulary Test-Chinese, parent-reported Adaptive Behavior
Assessment System-II, number of core vocabularies learned in the applied
communication learning system, Chinese child developmental inventory and
parenting stress index.
No comments:
Post a Comment